title: Vasoactive agent buflomedil up-regulated expression of vascular endothelial growth factor in a rat model of sciatic nerve crush injury.
abstract: OBJECTIVE
  To study the effect of Buflomedil on the morphological repair on crush injury of sciatic nerve and also the expression of vascular endothelial growth factor (VEGF).
  
  
  METHODS
  Rat sciatic nerves were crushed by pincers. All of the 400 Sprague Dawley rats were randomly divided into: Sham-operated; saline; saline + VEGF-antibody; Buflomedil; and Buflomedil + VEGF antibody groups. The expression of VEGF in dorsal root ganglia (DRGs), following crush injury to sciatic nerves, was studied by RT-PCR, immunohistochemistry. The effects of Buflomedil on expression of VEGF and repair of neural pathology were also evaluated.
  
  
  RESULTS
  VEGF mRNA was significantly increased in Buflomedil and Buflomedil + VEGF-antibody groups, compared with other groups. The number of VEGF-positive neurons was significantly increased in the Buflomedil and the saline groups. Besides, Buflomedil also caused less pathological changes in DRGs.
  
  
  CONCLUSIONS
  The vasoactive agent Buflomedil may decrease the pathological lesion and improve the functional rehabilitation of peripheral nerves, which may correlate to upregulation of the expression of VEGF, following crush injury to the peripheral nerves.
authors.affiliation: Department of Neurology, the First Affiliated Hospital of Nanjing Medical University, China.
authors.forename: Jin-Rong
authors.initials: JR
authors.lastname: Tang
authors.forename: Le
authors.initials: L
authors.lastname: Wu
authors.forename: Jian-Hua
authors.initials: JH
authors.lastname: Su
authors.forename: Ping
authors.initials: P
authors.lastname: Zhang
authors.forename: Long-Bin
authors.initials: LB
authors.lastname: Yu
authors.forename: Hang
authors.initials: H
authors.lastname: Xiao
mesh_terms: D000818:Animals; D004195:Disease Models, Animal; D005260:Female; D005786:Gene Expression Regulation / Q000187:drug effects*; D008297:Male; D009409:Nerve Crush / Q000379:methods; D011759:Pyrrolidines / Q000494:pharmacology / Q000627:therapeutic use*; D011897:Random Allocation; D051381:Rats; D017207:Rats, Sprague-Dawley; D020426:Sciatic Neuropathy / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D015854:Up-Regulation / Q000187:drug effects / Q000502:physiology*; D042461:Vascular Endothelial Growth Factor A / Q000096:biosynthesis*; D014662:Vasoconstrictor Agents / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D011759:Pyrrolidines; D042461:Vascular Endothelial Growth Factor A; D014662:Vasoconstrictor Agents; C467498:vascular endothelial growth factor A, rat; C010651:buflomedil
keywords: Crush injury; dorsal root ganglion; sciatic nerve; vascular endothelium growth factor; vasoactive agent